¹⁷⁷Lu-AMTG is a radiolabeled bombesin analogue developed at the Technical University of Munich, Germany as an improved alternative to ¹⁷⁷Lu-RM2 and ¹⁷⁷Lu-NeoBOMB1. Multiple preclinical studies have demonstrated receptor-specific accumulation of such molecules in gastrin-releasing peptide (GRP) positive tumors. ¹⁷⁷Lu-AMTG is a new Bombesin (BBN) analogue explored as therapeutic drug in indications such as prostate or breast cancer and shows a higher metabolic stability. The drug is just entering Phase I.

Target/Mechanism: GRPR

Carrier/Ligand: Bombesin

Radiation Type: beta electrons (β^–)